
We believe that data is key to disease prevention, management, and treatment. Our team knows how to turn complex data science into practical and intuitive solutions that make physicians' work easier. Yet beyond state-of-the-art technology, we're driven by the purpose of improving patients' lives. We made it our mission to provide AI that empowers healthcare and pharmaceutical professionals to deliver faster, more precise diagnostics and treatments. Our 60+ team of data scientists, software engineers, medical, regulatory, and business professionals cut through the hype around AI to build solutions tailored to the needs of clinicians and integrated into their workflow. Veye Lung Nodules, our CE certified solution for pulmonary nodule management, is currently used in clinical practice and lung cancer screening across Europe. Veye Lung Nodules supports the improvement of patient outcomes by ensuring faster results, lowering the risk of misdiagnosis, and helping to detect and segment early-stage lung cancer. Aidence is part of the AI division of RadNet, an US-based leading provider of diagnostic imaging services. Do you want to contribute to the creation of AI tools that will transform the healthcare industry? Are you ambitious and ready for a scale-up challenge? Glimpse into the Aidence life: http://bit.ly/lifeataidence Check our openings here: https://www.aidence.com/join-the-team/

We believe that data is key to disease prevention, management, and treatment. Our team knows how to turn complex data science into practical and intuitive solutions that make physicians' work easier. Yet beyond state-of-the-art technology, we're driven by the purpose of improving patients' lives. We made it our mission to provide AI that empowers healthcare and pharmaceutical professionals to deliver faster, more precise diagnostics and treatments. Our 60+ team of data scientists, software engineers, medical, regulatory, and business professionals cut through the hype around AI to build solutions tailored to the needs of clinicians and integrated into their workflow. Veye Lung Nodules, our CE certified solution for pulmonary nodule management, is currently used in clinical practice and lung cancer screening across Europe. Veye Lung Nodules supports the improvement of patient outcomes by ensuring faster results, lowering the risk of misdiagnosis, and helping to detect and segment early-stage lung cancer. Aidence is part of the AI division of RadNet, an US-based leading provider of diagnostic imaging services. Do you want to contribute to the creation of AI tools that will transform the healthcare industry? Are you ambitious and ready for a scale-up challenge? Glimpse into the Aidence life: http://bit.ly/lifeataidence Check our openings here: https://www.aidence.com/join-the-team/
What they do: CE‑marked AI (Veye Lung Nodules) for pulmonary nodule detection and management integrated into radiology workflows
Founded: 2015 in Amsterdam
Team size (approx.): 60–79 employees
Exit / ownership: Acquired by RadNet (announced Jan 24, 2022)
Notable investors: INKEF Capital (led 2019 Series A), Rabo Ventures; other backers include Northzone, henQ, Health Innovations
Medical imaging / radiology AI for lung cancer screening and pulmonary nodule management
2015
Medical Equipment Manufacturing
€10,000,000
Co-investor Rabo Ventures; existing investors included Northzone and Health Innovations
Aidence was acquired by RadNet
“Series A led by INKEF Capital with participation from Rabo Ventures, Northzone, henQ and Health Innovations”
| Company |
|---|